Global Vascular Endothelial Growth Factor Antibodies Market Trends & Industry Forecast by 2016 - 2024

Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market: Overview

Vascular endothelial growth factor is an integral part of several pathophysiological processes. This is the primary reason why it is extensively used for designing therapies to treat patients with macular degeneration and cancers. The global vascular endothelial growth factor (VEGF) antibodies is gaining momentum as it is known to be far more effective than conventional pharmaceuticals. Currently, VEGF antibodies used for treating cancer contribute more than half the total revenue of the global market. Some of the popular antibodies other than Avastin in the global market are Eylea (aflibercept, Bayer Pharma AG), Cometriq (cabozantinib, Exelixis, Inc.), Jetrea, Cyramza (ramucirumab, Eli Lilly and Company), Macugen (pegaptanib, Valeant Pharmaceuticals), Zaltrap (ziv-aflibercept, Regeneron Pharmaceuticals, Inc.), and Lucentis (ranibizumab, Genentech). 

The research report by Transparency Market Research provides a thorough outlook of the global VEGF antibodies market. The research report includes SWOT analysis and Porter’s five forces analysis for an in-depth understanding of the ever-changing market dynamics. The publication includes recommendations and comments by expert market leaders in order to help the readers gain holistic knowledge. The unbiased review of the market is aimed at providing guidance to the readers for making well-informed business decisions. For an accurate and an exact assessment of the information, the research report has been compiled using primary and secondary research methodologies. 

Obtain Report Details @
http://www.transparencymarketresearch.com/vascular-endothelial-growth-factor-antibodies-market.html

Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market: Key Trends

The global VEGF antibodies market is expected to see entry of several biosimilars manufacturing companies as first generation VEGR antibodies are reach their patent expiry. This trend has also opened up several opportunities for companies that have been developing next generation products. The launch of promising therapies in the foreseeable future will offer users tremendous convenience. 

The increasing investments in research and development are also expected to play an instrumental role in shaping the trajectory of the global market. For instance, increasing focus on developing personalize medicines and diagnostics will lead to generation of targeted therapies, thereby helping patients to receive optimized therapy. Efficient therapies and reduction of toxicities will ensure high uptake of these products in the near future. 

Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market: Regional Outlook

From a geographic point of view, the global VEGF antibodies market is segmented into Europe, North America, Asia Pacific, and Rest of the World. Of these, North America and Europe are projected to lead the global market in the coming years due a well-structured healthcare sector in the developed regions. Furthermore, growing diagnostic centers that have brought forth the increasing prevalence of cancer in the region have also augmented the demand for VEGF antibodies.

Analysts expect that developing regions of Africa and Asia Pacific are also expected to be lucrative markets for VEGF antibodies in the near future. Countries such as India and China are expected to dominate the Asia Pacific market as big players are looking at developing nations for expansion and collaborations. 

Key Players Mentioned in the Report are:

Some of the leading players operating in the global VEGF antibodies market are Genentech (a Roche company), Exelixis, Inc., Abcam plc, Eli Lilly and Company, Bayer Pharma AG, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals, Ceres Oncology Pty Ltd (a subsidiary of Circardian Technologies Limited), BioVision, Inc., and Santen Pharmaceutical Co. Ltd. The research report explains the competitive landscape present in the global VEGF antibodies market in the complete detail.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7286

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Gastrointestinal Electrocardiograph Market Key Trends & Industry Forecast 2015 - 2023

Gastrointestinal diseases are mild to chronic disorders related to gastrointestinal tract (GIT), which includes diseases related to esophagus, stomach, intestines, liver, pancreas and other associated body organs. Gastrointestinal diseases may or may not be life-threatening. Gastrointestinal disorders are usually chronic in nature and cause severe inflammation and irritation of bowel. 

A large number of diagnostic tests and tools are used in the diagnosis of gastrointestinal diseases. These techniques mainly include endoscopy, electrogastrograph (EGG), MRI scanning and CT scans. Gastrointestinal electrocardiograph, also known as electrogastrograph (EGG) is a technique to measure action potentials of the stomach. The main aim of measuring action potential of stomach is to evaluate gastric motility and to determine the relation between EGG and identify the diseases related to stomach and GIT. The physiological basis of EGG underlies the motility of GI tract. The motility of GI tract is based on contractions of smooth muscle, which in turn is based on two patterns of electrical activity, namely; action potential and slow waves. Slow waves in GIT are initiated by the interstitial cells of Cajal (ICC). The maximum frequency of muscle contraction ranges from 3 waves in a minute (stomach) to 17 waves per minute (rectum). 

Obtain Report Details @
http://www.transparencymarketresearch.com/gastrointestinal-electrocardiograph-market.html

The market of gastrointestinal electrocardiograph is segmented on the basis of types of EGG, such as electrogastroenterography (EGEG) and cutaneous electrogastrography. Further, the market is also segmented on the basis of applications (gastric diseases diagnosis), such as gastric cancer diagnosis, irritable bowel syndrome, functional dyspepsia, peptic ulcer, motility disorders (vomiting, nausea, delayed gastric emptying) and others. Moreover, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). Currently, the North American region is the most lucrative market, owing to large number of patients diagnosed with gastrointestinal diseases and increased demand for advanced diagnostic technologies. However, Asia-Pacific is considered as the most promising market during the forecast period from 2014 to 2020, owing to rising prevalence of disease and increasing awareness about the GIT diseases, its symptoms, diagnostic tests and treatment.

The global market for gastrointestinal electrocardiograph is anticipated to witness a steady growth during the forecast period from 2014 to 2020. This growth is likely to support by the factors such as high prevalence of gastric disorders, increased use of advanced diagnostic technologies and growing medical infrastructure and healthcare expenditure. Large prevalence of chronic gastrointestinal diseases is another important propeller of the market growth. According to a report of National Digestive Diseases Information Clearinghouse (NDDIC), in the U.S., around 70 million people were affected by various types of digestive diseases in 2010. The report further states that around 245,000 people were killed in 2009, due to gastrointestinal diseases. Thus, high prevalence of chronic gastric diseases accelerates the market growth. Furthermore, according to the statistics provided by the Office for National Statistics, Government of the U.K., the healthcare expenditure of the U.K. has expanded from USD 101.8 billion in 2000 to USD 233.4 billion in 2012. This exponential growth in the healthcare expenditure of the developed countries (the U.S., the U.K. and Japan) propells strong development of medical infrastructure, which ultimately supports the growth of gastrointestinal electrocardiograph market. On the other hand, high cost and lack of awareness are the key restraints that may limit the market growth to some extent.

Some of the major players operating in this market include Synectics Medical, 3CPM Company, and Gastroscan amongst others.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6865

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Patient Warming Devices Market to Reach US$2.78 bn by the end of 2024

Global Patient Warming Devices Market: Overview 

This report on the patient warming devices market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various patient warming devices such as surface warming devices as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global market with respect to the leading market segments based on major products, applications and geographies. 

Obtain Report Details @
http://www.transparencymarketresearch.com/patient-warming-devices-market.html

Global Patient Warming Devices Market: Key Segments 

The global patient warming devices market has been studied based on major product/device segments, application segments, and their regional as well as national markets. Based on product type, the global market has been categorized into three major segments: surface warming systems, intravascular warming systems, and patient warming accessories. Based on applications, the market has been categorized into four major segments: acute care, perioperative care, new born care, and others. Based on end user, the market has been categorized into four major segments: hospitals, clinics, nursing facilities and others. The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year. 

Global Patient Warming Devices Market: Scope of the Report 

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the patient warming devices market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. Porter’s five forces analysis is also provided in this section to understand the market considering the different parameters that have an impact on the sustainability of the companies operating in the market. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market. 

Global Patient Warming Devices Market: Regional Outlook 

Geographically, the global market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Each regional market for patient warming devices has been further categorized into major national markets such as the U.S, Canada, Germany, France, the U.K., Japan, China, India and Brazil. Market revenue in terms of USD million for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year. 

Companies Mentioned in the Report 

The recommendations section included in the report would assist existing market players in expanding their market shares, and new companies in establishing their presence in the global market. The report also profiles major players in the patient warming devices market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. The key players operating in the global market are 3M Health Care, ZOLL Medical Corporation, C. R. Bard, Inc., Smiths Medical, Stryker Corporation, Medtronic plc, GE Healthcare, Inspiration Healthcare (INDITHERM), and Philips Healthcare among others. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7877

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Hypertrophic Cardiomyopathy Therapeutics Market Global Industry Volume By Region 2015 - 2023

The rising prevalence of chronic cardiovascular ailments has spurred the demand for effective therapeutics, thereby driving the global hypertrophic cardiomyopathy (HCM) therapeutics market. In a report titled “Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023,” Transparency Market Research studies in detail the various factors fueling and challenging the global market. 

Obtain Report Details @
http://www.transparencymarketresearch.com/hypertrophic-cardiomyopathy-therapeutics-market.html
 
According to the American Heart Association, hypertrophic cardiomyopathy is a common condition that occurs when the muscle cells of the heart enlarge, causing the ventricle walls to thicken. HCM affects both men and women and is a common cause of sudden cardiac arrest in young people. The rising incidence of obstructive and non-obstructive hypertrophic cardiomyopathy is anticipated help the global market maintain a steady, albeit meager CAGR of 1.4% from 2015 to 2023. In 2014, the value of the hypertrophic cardiomyopathy therapeutics market was pegged at US$1.2 bn, which is forecast to increase to US$1.4 bn by 2023.

The global market for hypertrophic cardiomyopathy therapeutics has been studied on two fronts: By drug class and by geography.

Based on drug class, the hypertrophic cardiomyopathy therapeutics market has been categorized into calcium channel blockers, anticoagulants, beta adrenergic blocking agents, and antiarrhythmic agents. Although beta adrenergic blocking agents are the first preference for the treatment of obstructive as well as non-obstructive hypertrophic cardiomyopathy, calcium channel blockers form the largest segment in the overall market in terms of revenue. This can be attributed to the fact that the price of the latter blocking agents is much higher than that of the former.

By geography, the global hypertrophic cardiomyopathy therapeutics market comprises, Asia Pacific, North America, Europe, and Rest of the World. North America and Europe dominate the worldwide market, with the U.S. being the largest market for hypertrophic cardiomyopathy therapeutics. Accounting for a share of over 30% in 2014, the country is projected to retain is lead position throughout the forecast period. The hypertrophic cardiomyopathy therapeutics markets in Europe and North America are fueled by the rising prevalence of sedentary lifestyle among the younger population, the availability of modern healthcare infrastructure, and an increased presence of obesity. Growing awareness about hypertrophic cardiomyopathy and the various therapeutics available today has also significantly propelled the hypertrophic cardiomyopathy therapeutics market in these two regions.

Asia Pacific is predicted to be the fastest expanding market by 2023, fueled primarily by the rapid development in healthcare infrastructure, the increasing prevalence of various chronic diseases, and the growing awareness about various cardiac complications.

The report offers a detailed section on the competitive landscape of the global hypertrophic cardiomyopathy therapeutics market. The strengths, weaknesses, opportunities, and threats of each of the profiled players have also been examined in the report. Some of the promising companies in the hypertrophic cardiomyopathy therapeutics market are Teva Pharmaceuticals Limited, Gilead Sciences, Inc., Merck & Co., Inc., AstraZeneca plc, Concordia Healthcare Corp., Pfizer, Inc., Mylan N.V., Novartis AG, and Sanofi S.A.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7553

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Fragment-based Drug Discovery Market Analysis, Trends and Forecast by 2015 - 2023

Fragment-based Drug Discovery Market: Snapshot

The introduction of new techniques into the existing fragment-based drug discovery practices have created significant reductions in time and cost, driving the demand for such practices. Combinational chemistry and high-throughput screening are some of the more recently introduced practices that have helped make fragment-based drug discovery programs a lot faster and cheaper than before. 

Additionally, as the usage of fragment-based drug discovery grows in the field of discovering weaker inhibitors, biophysical techniques become extremely useful. These techniques can be used to measure binding within fragment compounds that possess low affinity for binding.

The demand for fragment-based drug discovery, however, is expected to be greatly hindered by the lowered potency of fragment screening, the most popular component, in certain compounds. The drugs generated have a lower than required potency, thus deterring several end users from approaching this technique.

The collective impact of all such drivers and restraints can be seen on the global fragment-based drug discovery market, which is expected to expand at a CAGR of 14.4% from 2015 to 2023 by revenue. By the end of 2016, this revenue is expected to reach US$435.6 mn and US$1.15 bn by the end of 2023.

Obtain Report Details @
http://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html

North America Expected to Continue Leading Demand for Fragment-based Drug Discovery Programs

By the end of 2023, the market value of fragment-based drug discovery techniques in North America is expected to be 45.4% of the global market. While this is a drop in market value from its 2014 statistic, North America will still enjoy being a leading geographical segment for advancements in fragment-based drug discovery techniques.

The key factors responsible for the leading role of North America in fragment-based drug discovery programs is the high rate of research and development efforts undertaken by prominent market players in the region. The U.S. and Canada are both countries with advanced healthcare systems and infrastructures, and are often the base of advanced technological implementations, making North America the hub for the latest developments in fragment-based drug discovery.

This region is also ramping up its speed in development of fragment-based drug discovery techniques by employing outsourcing facilities from Asia Pacific. The demand for fragment-based drug discovery in Asia Pacific, on the other hand, is a lot higher than any other major region, owing to the rapid improvements in healthcare infrastructure and focus on better quality management in countries such as Japan and China.

Biopharmaceutical Companies Top the List of Fragment-based Drug Discovery Demand

Fragment-based drug discovery techniques have grown significantly in popularity in the recent years and have found a great scope of use in the biopharmaceuticals. This includes large companies, academic bodies, and CROs. These techniques have helped massively in creating chemical series that possess lead-like properties as they have improved the success rate of creation significantly over the conventional screening methods. Fragment-based drug discovery techniques have also been extremely useful in marking out chemical motifs from multiple targets.

It is a combination of all these factors that are expected to drive the use of fragment-based drug discovery in biopharmaceutical facilities to a revenue generation of US$565.2 mn by the end of 2023. The key providers of fragment-based drug discovery programs include Astex Pharmaceuticals, Charles River Laboratories International, Inc., Sygnature Discovery, Evotec A.G., and Beactica AB.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.